• Patients in the 121 kg to 140 kg weight group randomized to apixaban were at comparable risk for major bleeding as those receiving warfarin, but tended to have lower rates of any bleeding
  • For patients in the >140 kg weight group, all-cause bleeding was comparable between both treatment arms
Event - Safety endpoints Rate (n) HR (95% CI)
Apixaban Warfarin Apixaban vs warfarin
Major bleeding      
 
121 to 140 kg 2.06 (13) 2.09 (14) 0.99 (0.46-2.10)
 
>140 kg 0.00 (0) 2.05 (5) -
 
Major or CRNM bleeding      
 
121 to 140 kg 2.54 (16) 5.55 (36) 0.46 (0.26-0.84)
 
>140 kg 3.51 (7) 2.90 (7) 1.21 (0.42-3.46)
 
Intracranial bleeding      
 
121 to 140 kg 0.00 (0) 0.44 (3) -
 
>140 kg 0.00 (0) 0.41 (1)) -
 
Gastrointestinal bleeding      
 
121 to 140 kg 0.62 (4) 0.15 (1) 4.27 (0.48-38.24)
 
>140 kg 0.00 (0) 0.82 (2) -
 
Any bleeding      
 
121 to 140 kg 15.15 (85) 25.63 (132) 0.61 (0.46-0.80)
 
>140 kg 20.86 (34) 23.74 (44) 0.89 (0.57-1.39)
 
0.01
0.1
1
10
100
Favors apixaban
Favors warfarin

The distribution of patients in each individual weight group was as follows: n = 724, 121 to 140 kg and n = 258, >140 kg.

1|2|3|4|5